Presentation title: Bacteriophages for Modulating Human Microbiome: The PhageBiotix™ and SuperBiotix™ Approaches and Their Potential Applications
Dr. Alexander “Sandro” Sulakvelidze, Ph.D. is the President and CEO of Intralytix. He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage-based food safety product in the World. Dr. Sulakvelidze has published extensively on the subject of phage therapy and biocontrol, including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of 15 issued and several pending patents in the field of bacteriophage technology.
There has been an increased interest in using bacteriophages for various applications ranging from food safety to human therapeutics, given their antibacterial efficacy and their ability to kill multidrug-resistant bacterial pathogens. Moreover, phages are increasingly being considered for targeted fine-tuning of the human microbiota for health benefits, either on their own or in combination with bacteria-based and/or yeast-based probiotics. Namely, the idea is to use lytic phages to gently modulate human microbiota, by killing specific pathogenic bacteria while preserving the commensal community. Such approaches may serve as platform technologies for developing a new class of drugs and/or nutritional supplements for improving human health via targeted microbiome modulation, which could be potentially used for managing both infectious (e.g. diarrhea) and non-infectious (e.g. certain forms of cancer) diseases that are linked to certain microbiome composition. The presentation will give the audience a current perspective about the history of bacteriophage therapy research and the crucial regulatory and human safety issues concerning the use of bacteriophages in various applications ranging from food safety to therapeutic applications.